Are you a #PrivateEquity, #InvestementBank, a Buy or Sell side #Analyst or a potential buyer in the world of pharma services and #eClinical Technology? Well this transaction by Thermofisher is a major move and there are more to come, especially within #eCOA and other tech utilized in #ClinicalTrials. Send me a DM at Joe Dustin or find me at www.joedustin.com if you would like to talk, setup a consult or learn more about this category that is heating up in activity. I've spent 20 years building eCOA in various roles across many companies. Experience is key. Alexander Despo, Ryan Silvester, Paul Wituschek, Richard Thomas, Laura Hilty, David Stevenson, Jeff Lee Jeff Kozloff, Austin Poole, Neeraj P., Vinay Shah, Dhruv Vasishtha, Chuka Esiobu, Jackson Monnin, Paul Moskowitz, Craig Lipset, AlphaSights GLG
This just in - Clario has just been acquired by Thermo Fisher Scientific for $8.8 Billion Dollars. For comparison - Medidata Solutions was acquired in 2019 for $5.8 Billion. Let that sink in. Clario is more than #eCOA - they have Imaging, Cardiac Safety, Respiratory solutions, etc. 70% of FDA Approvals in the last decade were using Clario for some sort of endpoint solution tech. There is no doubt they were a market leader and had proven their ability to deliver. That being said, the technology was aging and clients were never really "Satisfied" even if they could just get the job done. At the end of the day - getting the job done usually matters more in this case. So - Is a CRO still where good technology goes to die or was this just a smart financial transaction that will feed the services arm of a major enterprise and diversify their assets? Will PPD take this new tech in house as the CRO arm of Thermofisher, or will this be utilized across both research and healthcare? Bottom line - it is highly commendable to the many employees and leaders who worked so long and hard in building what became Clario. From the days ERT, PHT, and invivodata merged they who were pioneers in creating the category of #eCOA for #ClinicalTrials and their early work set the stage for industry adoption and even some early work in #DHT and Digital Biomarkers. As newer players entered the market, others figured out more modern ways to solve the problem, but Clario deserves massive credit for getting our industry to this point. They have also set the benchmark for the rest of the eCOA players who are considering some M&A events. The next 9 months should be interesting. If you are researching this category as a PE firm, investment bank or strategy consultant - -Send me a DM.-- I've spent 20 years in eCOA and Clinical Trials / Pharma Tech and there is a lot to learn :) #DigitalHealth #eCOA #ePRO #ClinicalTrials https://lnkd.in/e8ABXFUG